Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R209130 for Negative Symptoms of Schizophrenia
NCT00063297Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing R209130 with Placebo (2 arms). Primary endpoints: Efficacy of Study Drug and Safety and Side Effects. Started May 2003; status: completed.
02
Drugs
volinanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00063297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063297.